Alzheimers disease
Clinical trials for Alzheimers disease explained in plain language.
Never miss a new study
Get alerted when new Alzheimers disease trials appear
Sign up with your email to follow new studies for Alzheimers disease, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new pill change the Brain's activity in early Alzheimer's?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called E2511 in people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia. The study aims to see if E2511 affects a specific brain signal measured by PET scans, and to check i…
Matched conditions: ALZHEIMERS DISEASE
Phase 1 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for Alzheimer's: safety trial of Add-On therapy begins
Symptom relief Not yet recruitingThis study tests whether adding an experimental drug (X/T+X-EC) to standard Alzheimer's treatment (lecanemab) is safe and tolerable. About 60 adults with Alzheimer's will receive either the drug or a placebo for 24 weeks. The main goal is to check for side effects, not to measure…
Matched conditions: ALZHEIMERS DISEASE
Phase 2 • Sponsor: Neurology Office of South Florida • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Can Real-World data reveal hidden risks of an Alzheimer's drug?
Knowledge-focused Not yet recruitingThis study is a registry that follows 400 people with Alzheimer's disease who have been prescribed LEQEMBI in routine clinical practice. The goal is to track how often and how severely certain side effects occur, including brain swelling (ARIA-E), small brain bleeds (ARIA-H), lar…
Matched conditions: ALZHEIMERS DISEASE
Sponsor: Eisai Limited • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?
Knowledge-focused Not yet recruitingThis registry study follows 400 Alzheimer's patients in Canada who are prescribed LEQEMBI, a medication for the disease. The goal is to track the frequency and severity of known side effects, such as brain swelling (ARIA-E), microbleeds (ARIA-H), and larger brain hemorrhages, dur…
Matched conditions: ALZHEIMERS DISEASE
Sponsor: Eisai Limited • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC